$PPCB
Propanc Biopharma, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045664 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $61.71K
YoY Change 279.97%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $290.8K
YoY Change -30.3%
Operating Profit -$290.8K
YoY Change -30.3%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$63.52K
YoY Change -195.73%
Pretax Income -$354.3K
YoY Change 0.98%
Income Tax
% Of Pretax Income
Net Earnings -$354.3K
YoY Change 0.98%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 789.9M shares 688.0M shares
Diluted Shares Outstanding 590.9M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $9.268K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.53K
YoY Change -85.23%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $42.11K
YoY Change 21.82%
TOTAL ASSETS
Total Short-Term Assets $21.53K
Total Long-Term Assets $42.11K
Total Assets $63.64K
YoY Change -64.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.239M
YoY Change 14.54%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.101M
YoY Change 30.9%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $70.49K
YoY Change 93.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.101M
Total Long-Term Liabilities $70.49K
Total Liabilities $4.172M
YoY Change 31.62%
SHAREHOLDERS EQUITY
Retained Earnings -$67.05M
YoY Change 2.88%
Common Stock $688.0K
YoY Change 4538.45%
Preferred Stock
YoY Change
Treasury Stock (at cost) $46.48K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$4.108M
YoY Change
Total Liabilities & Shareholders Equity $63.64K
YoY Change -64.71%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$354.3K
YoY Change 0.98%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$235.5K
YoY Change -29.37%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $215.7K
YoY Change -38.43%
NET CHANGE
Cash From Operating Activities -$235.5K
Cash From Investing Activities
Cash From Financing Activities $215.7K
Net Change In Cash -$11.82K
YoY Change 245.32%
FREE CASH FLOW
Cash From Operating Activities -$235.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
6 Butler Street
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Camberwell
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
3124
CY2024Q3 dei Entity Address Country
EntityAddressCountry
AU
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
9882-0780
CY2024Q3 us-gaap Cash
Cash
9268 usd
CY2024Q3 PPCB Goods And Services Tax Receivable Current
GoodsAndServicesTaxReceivableCurrent
3309 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8957 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
21534 usd
CY2024Q3 us-gaap Assets
Assets
63644 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1238589 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
875199 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
111652 usd
CY2024Q3 dei Amendment Flag
AmendmentFlag
false
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0662986
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
302
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001517681
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q3 PPCB Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants
StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants
usd
CY2023Q3 PPCB Stock Issued During Period Value Issuable Shares
StockIssuedDuringPeriodValueIssuableShares
usd
CY2023Q3 PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants
DeemedDividendUponAlternateCashlessExerciseOfWarrants
usd
CY2023Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
CY2024Q3 us-gaap Depreciation
Depreciation
usd
CY2024Q3 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
CY2024Q3 PPCB Increase Decrease In Refundable Advance Deposit
IncreaseDecreaseInRefundableAdvanceDeposit
usd
CY2024Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
CY2024Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2024Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q3 PPCB Relative Fair Value Of Warrant Granted In Connections With Loan Payable Related Party
RelativeFairValueOfWarrantGrantedInConnectionsWithLoanPayableRelatedParty
usd
CY2024Q3 PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1
DeemedDividendUponAlternateCashlessExerciseOfWarrants1
usd
CY2023Q3 us-gaap Stock Issued1
StockIssued1
usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2024Q3 us-gaap Depreciation
Depreciation
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2024Q3 PPCB Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Entity File Number
EntityFileNumber
000-54878
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
PROPANC BIOPHARMA, INC.
CY2024Q3 dei City Area Code
CityAreaCode
+61-03
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
789899183 shares
CY2024Q3 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q2 us-gaap Cash
Cash
21085 usd
CY2024Q2 PPCB Goods And Services Tax Receivable Current
GoodsAndServicesTaxReceivableCurrent
2950 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1406 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
25441 usd
CY2024Q3 us-gaap Deferred Costs
DeferredCosts
27117 usd
CY2024Q2 us-gaap Deferred Costs
DeferredCosts
27117 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2081 usd
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2008 usd
CY2024Q2 us-gaap Assets
Assets
72365 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1213335 usd
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
792190 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
94612 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
213109 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
204694 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
381789 usd
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
399325 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
134234 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
133886 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
677902 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
639371 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4101244 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3792782 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
70485 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
58642 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4171729 usd
CY2024Q2 us-gaap Liabilities
Liabilities
3851424 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500005 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500005 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
688022017 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
688022017 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
478802488 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
478802488 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
688022 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
478802 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61132262 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61217255 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1170638 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1269581 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67052530 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66698220 usd
CY2024Q3 PPCB Treasury Stock Price Per Share
TreasuryStockPricePerShare
0.001
CY2024Q2 PPCB Treasury Stock Price Per Share
TreasuryStockPricePerShare
0.001
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
46477 usd
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
46477 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108085 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3779059 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63644 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72365 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
220759 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
393828 usd
CY2024Q3 us-gaap Occupancy Net
OccupancyNet
8317 usd
CY2023Q3 us-gaap Occupancy Net
OccupancyNet
7149 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61714 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16242 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
290790 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
417219 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-290790 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-417219 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
86230 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
178234 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
1 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
17 usd
CY2024Q3 PPCB Derivative Expense
DerivativeExpense
27182 usd
CY2023Q3 PPCB Derivative Expense
DerivativeExpense
77721 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
52787 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
303929 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11319 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
34310 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
8423 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-15948 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63520 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
66353 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-354310 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-350866 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-354310 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-350866 usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
142575 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-354310 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-493441 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
590937498 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
590937498 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10989681 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10989681 shares
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-354310 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-493441 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-98943 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
73674 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-98943 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
73674 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-453253 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-419767 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3117179 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
229190 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
34838 usd
CY2023Q3 PPCB Relative Fair Value Of Warrant Granted In Connection With Loan Payable Related Party
RelativeFairValueOfWarrantGrantedInConnectionWithLoanPayableRelatedParty
141084 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
73674 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-350866 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-2989259 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3779059 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3779059 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
99891 usd
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
9336 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-98943 usd
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-98943 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-354310 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-354310 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108085 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108085 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-354310 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-350866 usd
CY2024Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
7500 usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
8423 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-15948 usd
CY2023Q3 us-gaap Depreciation
Depreciation
134 usd
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
56983 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
69457 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5534 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5128 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
52787 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
303929 usd
CY2024Q3 PPCB Derivative Expense
DerivativeExpense
27182 usd
CY2023Q3 PPCB Derivative Expense
DerivativeExpense
77721 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11319 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
34310 usd
CY2024Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
2548 usd
CY2023Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
1437 usd
CY2023Q3 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-88846 usd
CY2024Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
251 usd
CY2023Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-132 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14468 usd
CY2023Q3 PPCB Increase Decrease In Refundable Advance Deposit
IncreaseDecreaseInRefundableAdvanceDeposit
116169 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-18797 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148834 usd
CY2024Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
15317 usd
CY2023Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
12275 usd
CY2024Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
54457 usd
CY2023Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
55693 usd
CY2024Q3 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
24093 usd
CY2023Q3 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
15712 usd
CY2024Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5880 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5032 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-235515 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-333457 usd
CY2024Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
60000 usd
CY2023Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
220000 usd
CY2023Q3 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
142909 usd
CY2023Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
120000 usd
CY2024Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
155699 usd
CY2023Q3 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
153256 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215699 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
350347 usd
CY2024Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7999 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-20312 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11817 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3422 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21085 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10047 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9268 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6625 usd
CY2024Q3 us-gaap Interest Paid Net
InterestPaidNet
2606 usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
2713 usd
CY2024Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
9336 usd
CY2023Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
34838 usd
CY2024Q3 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
51978 usd
CY2023Q3 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
114131 usd
CY2024Q3 PPCB Debt Discounts Related To Derivative Liability
DebtDiscountsRelatedToDerivativeLiability
60000 usd
CY2023Q3 PPCB Debt Discounts Related To Derivative Liability
DebtDiscountsRelatedToDerivativeLiability
70000 usd
CY2023Q3 PPCB Relative Fair Value Of Warrant Granted In Connections With Loan Payable Related Party
RelativeFairValueOfWarrantGrantedInConnectionsWithLoanPayableRelatedParty
141084 usd
CY2023Q3 PPCB Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1
DeemedDividendUponAlternateCashlessExerciseOfWarrants1
142575 usd
CY2024Q3 us-gaap Stock Issued1
StockIssued1
7500 usd
CY2023Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
one-for-one thousand (1:1,000)
CY2024Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_ziuYMQyjqlz6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zeQzeTTpEPha">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives of long-lived assets, valuation of the collectability of a refundable advance deposit, present value of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROPANC BIOPHARMA, INC. AND SUBSIDIARY</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2024</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
677000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
669000 usd
CY2024Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.6936 pure
CY2024Q2 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.6693 pure
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1269581 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-98943 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1170638 usd
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 PPCB Refundable Advance Deposit
RefundableAdvanceDeposit
120958 usd
CY2024Q3 PPCB Allowance For Recoverability Of Refundable Advance Deposit
AllowanceForRecoverabilityOfRefundableAdvanceDeposit
120958 usd
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
27117 usd
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
27117 usd
CY2024Q3 PPCB Goods And Services Tax Receivable Current
GoodsAndServicesTaxReceivableCurrent
3309 usd
CY2024Q2 PPCB Goods And Services Tax Receivable Current
GoodsAndServicesTaxReceivableCurrent
2950 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61714 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16242 usd
CY2024Q3 us-gaap Debt Instrument Convertible Terms Of Conversion Feature
DebtInstrumentConvertibleTermsOfConversionFeature
Each holder of the convertible notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
CY2024Q3 us-gaap Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger
DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
0.0499 pure
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13004861540.12 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11396197211.12 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-354310 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-235515 usd
CY2024Q3 PPCB Working Capital Deficit
WorkingCapitalDeficit
4079710 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4108085 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67052530 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26471 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25543 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26471 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25543 usd
CY2023Q3 us-gaap Depreciation
Depreciation
134 usd
CY2023Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
334625 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
313550 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
68129 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
38854 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
115293 usd
CY2024Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
124629 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
381789 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
399325 usd
CY2024Q3 PPCB Debt Instrument Debt Default Interest Rate
DebtInstrumentDebtDefaultInterestRate
0.24 pure
CY2024Q3 PPCB Debt Instrument Debt Default Interest Rate
DebtInstrumentDebtDefaultInterestRate
0.24 pure
CY2024Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
9336 usd
CY2023Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
34838 usd
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2022Q2 PPCB Number Of Preferred Stock Authorized Shares
NumberOfPreferredStockAuthorizedShares
1500005 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3001500005 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000000 shares
CY2022Q3 PPCB Number Of Preferred Stock Authorized Shares
NumberOfPreferredStockAuthorizedShares
1500005 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
10001500005 shares
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-one thousand (1:1,000)
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500005 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
30800 usd
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
2212 usd
CY2024Q3 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
798 usd
CY2024Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
45365 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
34046 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11319 usd
CY2024Q3 PPCB Reclassified From Premium Liabilities To Additional Paid In Capital
ReclassifiedFromPremiumLiabilitiesToAdditionalPaidInCapital
9336 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
15003396 shares
CY2024Q2 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding
1.24
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
15003396 shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding
1.24
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
15003378 shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable
1.24
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms
P1Y9M3D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
15003396 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
15003396 shares
CY2024Q3 PPCB Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
15003378 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0.059 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4533000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0.059 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4533000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0.059 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4533000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M13D
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
0 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse stock split of the Company’s issued and outstanding shares of common stock at a ratio of one post-split share per sixty thousand pre-split shares (1:60,000) (the “Reverse Stock Split”).
CY2024Q3 PPCB Penalty Amount
PenaltyAmount
30000 usd
CY2020Q4 PPCB Royalties Percentage
RoyaltiesPercentage
0.02 pure
CY2024Q3 PPCB Unreimbursed Lab Fees
UnreimbursedLabFees
54327 usd
CY2024Q2 PPCB Unreimbursed Lab Fees
UnreimbursedLabFees
47531 usd
CY2024Q3 us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2024 us-gaap Royalty Expense
RoyaltyExpense
0 usd
CY2024Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q2 PPCB Incremental Borrowing Rate
IncrementalBorrowingRate
0.08 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
14566 usd
CY2024Q3 us-gaap Receivable With Imputed Interest Net Amount
ReceivableWithImputedInterestNetAmount
381 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14185 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M3D
CY2024Q3 us-gaap Payments For Rent
PaymentsForRent
8317 usd
CY2023Q3 us-gaap Payments For Rent
PaymentsForRent
7149 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
71629 usd
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
71629 usd
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
85000 aud
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
57639 usd
CY2023 PPCB Bonus Payable
BonusPayable
73387 aud
CY2023 PPCB Bonus Payable
BonusPayable
48905 usd
CY2024 PPCB Bonus Payable
BonusPayable
25000 aud
CY2024 PPCB Bonus Payable
BonusPayable
16070 usd
CY2024Q1 PPCB Bonus Payable
BonusPayable
150000 aud
CY2024Q1 PPCB Bonus Payable
BonusPayable
102195 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
161500 aud
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
112016 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
148000 aud
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
97044 usd
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6000 usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
34500 usd
CY2024Q3 us-gaap Share Price
SharePrice
0.0003
CY2024Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
134234 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
134234 usd
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
133886 usd
CY2024Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
133886 usd

Files In Submission

Name View Source Status
0001493152-24-045664-index-headers.html Edgar Link pending
0001493152-24-045664-index.html Edgar Link pending
0001493152-24-045664.txt Edgar Link pending
0001493152-24-045664-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
ppcb-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
ppcb-20240930_cal.xml Edgar Link unprocessable
ppcb-20240930_def.xml Edgar Link unprocessable
ppcb-20240930_pre.xml Edgar Link unprocessable
ppcb-20240930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable